SVRA catalyst calendar

Savara Inc

Upcoming catalysts
1
Cash runway
15.7 months
Cash & investments
$173M
Phase 3 programs
4

Savara Inc is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). on June 15, 2027. There is 1 upcoming event on record.

Cash runway is approximately 15.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 8 concluded trials, 75% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
June 15, 2027 Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). Trial Milestone Phase 3

Track SVRA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open SVRA in the tracker

Recent history

DateEventTypePhase
June 8, 2026 8-K filed: Leadership change Corporate —
March 13, 2026 8-K filed: Material agreement Corporate —
January 27, 2026 8-K filed: Material agreement Corporate —
January 9, 2026 8-K filed: Reg FD disclosure Filing —
October 30, 2025 8-K filed: Material agreement, Other event Corporate —
October 29, 2025 8-K filed: Material agreement, Reg FD disclosure, Other event Corporate —
September 2, 2025 8-K filed: Reg FD disclosure Filing —
May 27, 2025 8-K filed: Other event Filing —
November 30, 2023 Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial Milestone Phase 3
January 14, 2021 Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Trial Milestone Phase 3
October 2, 2020 Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection Trial Milestone Phase 2
July 28, 2020 AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis Trial Milestone Phase 3
October 15, 2019 Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection Trial Milestone Phase 2
April 19, 2019 Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.